Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem

SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia
In the SHASTA-3 and SHASTA-4 trials, quarterly administration of plozasiran reduced triglyceride (TG) levels and acute pancreatitis (AP) events in individuals with severe hypertriglyceridaemia (sHTG; TG ≥500 mg/dL).

Tailored therapy reduces antibiotic use in infective endocarditis
A response-tailored strategy decreases antibiotic duration by 2 weeks compared with standard therapy in patients with left-sided infective endocarditis, without compromising their safety. This is the primary result of the POET-II study presented at ESC Congress 2026.

Add-on tafasitamab–lenalidomide improves PFS in BCLs
In the global phase III frontMIND study, adding tafasitamab and lenalidomide (Tafa-Len) to an R-CHOP* chemotherapy regimen significantly improves progression-free survival in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade BCL (HGBCL).





